Blood sugar
The label warns that tesamorelin can raise blood sugar.
Read the evidence and its limits.
Ask who was studied, what changed, and what those results can tell you about your own goal.
Within the HIV study group
Keep the trial group in view.
As of September 2026, US approval covers tesamorelin (EGRIFTA SV, EGRIFTA WR) for reducing excess belly fat in adults with HIV who also have lipodystrophy.
HIV is a virus that weakens the body’s ability to fight infections.
Lipodystrophy means changes in how the body stores fat that can occur with HIV treatment.
As of September 2026, the Food and Drug Administration (FDA), the US drug regulator, has not approved tesamorelin for weight loss.
The medicine’s label is its official information about uses and cautions.
Read the scope of approval
The main study
Deep belly fat fell. Body weight barely changed.
In a study published in 2007, researcher Falutz and his team followed 412 adults who had HIV and extra belly fat.
Deep belly fat means fat around the organs inside the belly.
Placebo means a dummy treatment without the active study medicine.
In that paper, deep belly fat fell about 15% with tesamorelin and rose about 5% with placebo over 26 weeks.
The label’s main trials showed little change in body weight.
In the later part of the studies, people switched to placebo regained belly fat over the next 26 weeks.
Ask how the findings relate to your concern and which changes would count as useful progress for you.
Open the trial and follow-up sources
The limit to keep
Check the evidence for your own goal.
As of September 2026, tesamorelin has no FDA approval for memory problems or ageing.
If that is your goal, ask which study fits you, what it measured, and what remains unknown.
Open the studies on thinking tests
Research on a different use is not proof of FDA approval for that use.
What the label flags
Bring these cautions into the visit.
The cautions below are in the official medicine information available in September 2026.
Fluid build-up
The label links fluid build-up to swelling, sore joints, and hand tingling from a squeezed nerve in the wrist.
A body signal can rise too high
IGF-1 is a body signal that helps cells grow; the label says the effects of high levels over a long time are unknown.
The label says doctors need to test IGF-1 during treatment and consider stopping treatment if it stays too high.
Ask what tests you need and what results would change your treatment.
Heart and blood vessels
The label says it is not known whether long-term use is safe for the heart and blood vessels.
Open the label cautions
Plain words
Find a term you just read.
Read the meanings below. If a search box is shown, type a word such as “blood” to show matching meanings. Use “Clear” to show the full list again.
All words are shown.
- Peptide
- Protein building blocks linked in a chain.
- FDA approval
- Permission for a specific medicine and a named use.
- Lipodystrophy
- A change in where fat is stored, which can come with HIV treatment.
- Telehealth
- A health visit by video, phone, or online messages.
- Compounding
- Preparing medicine for an order in place of supplying a ready-made product.
- Biologic
- For tesamorelin, this means a medicine made from a long chain of protein building blocks. US law bars pharmacies from making their own copies of it, as of September 2026.
- Placebo
- A dummy treatment without the active medicine being studied.
- Blood sugar
- Glucose is the medical word for blood sugar.
- Growth hormone
- A body signal that helps build body tissue and break down fat.
- IGF-1
- A body signal that helps cells grow. Tesamorelin makes the body release more growth hormone, which raises this signal.